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Abstract. We evaluated the feasibility of using a blockchain technology to create
a traceability solution for pharmaceutical drugs that would promote compliance
with recent legislation. Counterfeit and other illegitimate pharmaceutical drugs
threaten patient safety, drug efficacy, and patient trust. The purpose of the Drug
Supply Chain Security Act (DSCSA) is to greatly reduce distribution of
illegitimate drugs by requiring all pharmaceuticals to be serialized and traceable
from the manufacturer through the supply chain to the dispenser. A software
application to serialize and track pharmaceuticals must overcome numerous
obstacles. In particular, the solution must provide a high degree of trust while
also protecting privacy for manufacturers, distributors, and patients. This
research will propose that a blockchain-enabled application will solve for many
of the most challenging needs for this solution.

1

Introduction

The Drug Quality and Security Act (DQSA); enacted November 2013; set requirements
for the compounding safety and security of pharmaceutical products. The law has two
focus areas. Title I is “The Compounding Quality Act”, which set standards for safety
and security for compounded drugs. Title II of DQSA is the “Drug Supply Chain
Security Act” (DSCSA). The DSCSA is further divided into two focus areas. One effort
establishes license and registration requirements for all wholesale distributors and
third-party logistics (3PL) providers to ensure proper identification of all legitimate
members of the supply chain. The second effort requires the consistent traceability of
pharmaceutical products from the manufacturer to the dispenser within the United
States. Participants in the supply chain are expected to verify the chain of ownership,
detect suspicious activity, and respond accordingly as outlined by the law. In addition,
participants must be able to quickly respond to requests for information from
enforcement officials. The final outcome of Title II will be the creation of an electronic,
interoperable traceability system for pharmaceutical products at the package-level by
2023 [1]. The goal is to use real-time data capture to detect, respond to, and report
potentially illegitimate drugs faster and more effectively before they can become a
safety hazard to patients.1
1

AmerisourceBergen. (2017). Serializing Your Products [White Paper].
https://www.icsconnect.com/insights/serializing-your-products.
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The DSCSA was created to curb the circulation and sale of illegitimate
pharmaceutical products. Illegitimate drug products jeopardize consumer safety and
cost the pharmaceutical industry almost $40 billion annually [2]. By serializing the
products and providing traceability from manufacturer to dispenser, participants in the
supply chain can be protected and have greater assurance of encountering only
legitimate pharmaceutical products. However, achieving this goal requires creating a
reliable system of record with appropriate visibility to identify legitimate
pharmaceuticals for all participants in the supply chain. Since members in the supply
chain have compelling business reasons not to share information on inventory, a key
challenge to ensuring compliance with traceability requirements will be establishing
trust among stakeholders.
Blockchain distributed ledger technology is causing controversy in the industry, with
some touting its capability to revolutionize computing while others are not convinced.
Gartner lists blockchain as on ‘the peak of inflated expectations’. 2 In an attempt to
clarify the real opportunity for blockchain, SAP surveyed “hundreds of organizations
currently engaged in blockchain-related activities”. Of the people surveyed, 92%
believe blockchain represented a new opportunity in the marketplace and of those 63%
sited supply chain applications as the most promising use cases for the technology. 3
Blockchain applications are appropriate when trying to introduce trust into a trust-less
system. As such, providing traceability of pharmaceuticals through the supply chain is
a suitable use case for a blockchain implementation. This review demonstrates how a
blockchain technology can provide functionality that benefits supply chain in general,
and traceability of pharmaceuticals in particular.
The case for the feasibility of blockchain for pharmaceutical supply chain is built by
first delving into the pharmaceutical supply chain and the DSCSA in sections 2 and 3
respectively. Then we present the characteristics of a blockchain distributed ledger in
the context of supply chain applications in section 4. In section 5, we explore how
blockchain is currently being implemented in supply chain applications. . The paper
concludes with ethical considerations presented in section 6, conclusions in section 7
and a summary in section 8. As this project was originally initiated as a Proof of
Concept, efforts to build the POC are outlined in the Appendix.

2

Pharmaceutical Supply Chain

The pharmaceutical supply chain is comprised of excipient manufactures, the
manufacturer of the drug, repackagers, wholesalers, logistics partners, and ultimately
the dispenser. The FDA provides a simplified illustration of the pharmaceutical supply
chain presented below.4

2
3
4
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FDA. A Drug Supply Chain Example.
https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM277651.pdf.
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Fig 1. FDA: Simplified View of the Pharmaceutical Supply Chain

Despite the simplified diagram, the pharmaceutical supply chain spans many
geographical regions and involves numerous parties. The pharmaceutical supply chain
contains excipient manufacturers. Excipients are substances other than the
pharmacologically active drug which are included in the manufacturing process or are
contained in a finished pharmaceutical product5. Only 6 percent of pharma sales are
direct from the manufacturer. Various regulations for things such as
Medicare/Medicaid compensation and transparency regarding cost revelation from
drug wholesalers and manufacturers continually impact the decision-making of pharma
supply chain managers and most product flow through a complex web of
manufacturers, repackagers, and wholesalers.[3] Repackagers are companies that buy
drugs from a manufacturer or a wholesale distributor and then put the drug into a new
package type, such as putting the drug into a smaller quantity package or moving units
from bottles into a blister card. Transfer of the drug from the manufacturer can be to a
repackager, a wholesaler, or directly to a dispenser; such as a hospital, non-specialty
pharmacy distributor, or specialty pharmacy. A wholesaler may warehouse the product
before selling and transporting to another wholesaler or a dispenser. The end of the
pharmaceutical supply chain is the dispensing of the drug to a patient.
The complex nature of the pharmaceutical supply chain includes the fee-for-service
model between the wholesaler and manufacturer. Contracts between drug
manufacturers and wholesalers help ensure that wholesalers maintain a supply agreed
upon by the manufacturer and wholesaler in exchange for a fee paid to the wholesaler
by the manufacturer. This arrangement helps the manufacturer to adequately procure
raw materials for their drug and to manufacture their drug in accordance with likely
demand. Without this contract in place, wholesalers may buy in excess to hedge against
price increases which would artificially inflate demand [4].
5

Rutesh, H. Dave, (2008). Overview of pharmaceutical excipients used in tablets and
capsules.
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GlobalData predicts that the estimated value of the US Pharmaceutical market will
increase from just under $400 billion in 2014 to almost $550 Billion by 2020 [5]. The
complexity of the supply chain increases as new drugs and new types of drugs are
developed, more functions are outsourced globally, modern technology is introduced,
and new regulations are enacted. Considering the increasing complexity of the supply
chain and the enormous monetary value at stake, it’s not surprising that securing the
pharmaceutical supply chain both urgent and challenging.
2.1

Risks in Pharmaceutical Supply Chain

The top three risks to the supply chain are 1) theft or diversion, 2) introduction of
counterfeit medicines, and 3) contamination of medicines during manufacturing,
storage, or distribution [5]. A diverted product has been removed from the normal
United States supply chain and then reintroduced for sale. This may include a drug
labeled for sale outside the US but then introduced into the US market, or a drug
transported outside of the US but then reintroduced within the US supply chain [6].
Provenance and authenticity are hard to verify for diverted drugs, raising questions
about safety and effectiveness. According to the FDA, a counterfeit drug is one in which
the container or labeling falsely represents a stakeholder in the supply chain, such as
the manufacturer, processor, packer, or distributor of the drug. A counterfeit drug is
sold with the intent to defraud and represents numerous risks to the consumer.
Examples include products that contain none of the active ingredient, an inappropriate
dosage of the active ingredient, or ingredients not on the label. The product may have
ingredients not in the original, meaning the specific combination has not been tested or
approved by the FDA. In 2008, a counterfeit version of the blood thinner heparin may
have contributed to the deaths of 81 people in the United States [5].
Typically, the objective of a supply chain is to maximize overall value created.
Supply chain management often focuses on cost reductions and efficiencies to achieve
that goal [7]. Considering the many avenues for fraud with potentially significant
adverse consequences for the patient, pharmaceutical supply chain management must
prioritize safety for the end user. Often, added safety measures and cost controls are
opposing goals. The DSCSA is first seeking to assure the safety of the pharmaceutical
supply chain by decreasing and detecting incidents representing the top risks of theft,
diversion and counterfeiting, but in doing so may also protect supply chain participants
from significant financial loss as well.
2.2

Lack of Integration across Pharmaceutical Supply Chain

As complex as the physical supply chain is, the information flow, document exchange,
and payment processes are even more complex. Think of each organization in the chain
as having its own inventory/receiving/payables/accounting systems behind their
firewall. These systems represent a myriad of different platforms, protocols, database,
and data models, each operating independently within each participant with no inherent
trust across the supply chain. In fact, within one supplier, systems may be operating
with limited integration. Even as operations move to the cloud, the systems are still
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independently owned and operated, with each entity owning their data if not the
applications and infrastructure. Connecting this collaboration of buyers and sellers is
an array of third-party data transfer services that ‘map’ the buyer’s data to the seller’s
data to facilitate electronic transfers of orders and other information. Electronic Data
Interchange (EDI), Hub models and cloud integration solutions provide some
connectivity, but there is no common data model used end-to-end across the supply
chain [8]. Plus, even with electronic transfer and data interchange, some level of manual
intervention frequently remains. For example, a person may need to enter the order, and
someone on the dock has to receive the shipment and verify the count and contents.
These activities may require manual data entry that introduces an opportunity for
human error.
Along with other perishable products, pharmaceutical products are increasingly
monitored for temperature and other environmental conditions during shipping and
storage. Drugs can be rendered ineffective if exposed to adverse environmental
conditions. Leveraging RFID technology and the connectedness of the Internet of
Things (IoT), more companies are piloting programs to embed sensors within product
shipments then monitor and analyze the resulting data to be sure the quality of the
product was not compromised as well as to be able to track and locate containers in a
shipment [9]. While obviously providing value and increasing safety, this also creates
more complexity as that data must be received, analyzed, and used as part of the
contractual agreement.
Furthermore, each participant may have a financial partner, such as a bank,
performing trade finance functions on their behalf. For example, the seller’s bank will
guarantee that the seller can supply the product and has delivered what was agreed. The
buyer’s bank guarantees that the buyer has received what was delivered and is able to
pay. Banks may provide letters of credit, document collection, buyer/seller credit, bank
guarantees, trades insurance, and other trade finance services to participants in the
supply chain. The need for trusted intermediaries effectively doubles the participants in
the transaction and drives complexity [8].
Theoretically, if the parties were sharing a blockchain, these trade services could be
eliminated, but that is outside the scope of what is required by the DSCSA, but the
requirement to provide traceability of drugs is a core requirement within the
information flow of the pharmaceutical supply chain. If there were an end-to-end data
exchange standard already defined for the pharmaceutical supply chain, then perhaps
implementing DSCSA would not be as large a challenge.

3

Drug Supply Chain Security Act (DSCSA)

The DSCSA stipulates the drugs and drug transactions that are covered by the act. The
DSCSA applies to all prescription drugs in “finished dosage form for administration to
a patient without further manufacturing” [1]. Excipient manufactures are excluded from
provisions. The DSCSA does not apply to blood or blood components intended for
transfusion, radioactive drugs or biologics, imaging drugs, certain IV products, medical
gas, homeopathic drugs, and lawfully compounded drugs. The DSCSA applies to all
transactions where a change of ownership occurs unless specifically exempted.
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Exemptions include intracompany distributions, distributions among hospitals under
common control, public health emergencies, dispensing pursuant to a prescription, and
transfer of approved animal drugs [1].
The primary activity being regulated is the transfer of ownership of the
pharmaceutical. With each change in ownership, “product tracing information” should
be exchanged and consists of three types of information:
Transaction Information (TI). The TI includes name of the product, the strength
and dosage form, the National Drug Code (NDC) number, the container size for
individual saleable units, the lot number, the date of the transaction, the date of
shipment, and the business name and address from whom and to whom ownership is
being transferred.[1] The NDC is a three-segment number comprised of the labeler
code, the product code, and the package code. The FDA publishes the NDC numbers
for finished drugs in the NDC Directory, which is updated daily. Future requirements
may also include the number of containers, meaning the number of individually
saleable units within the lot [10].
Transaction History (TH). The TH details the transaction information above for
each prior transaction going back to the manufacturer of the product. This information
establishes the chain of ownership that validates the pharmaceutical is legitimate.[1]
Transaction Statement (TS). The TS establishes accountability under the law for
the entity transferring ownership. The entity transferring ownership attests that they:
are properly authorized under DSCSA, received the product from an entity authorized
under DSCSA, received TI and TS from the prior owner as required under the law, did
not knowingly ship a suspect product, have systems and processes in place to comply
with verification requirements, did not knowingly provide false transaction
information, and did not knowingly alter the transaction history [1].
Any entity who takes ownership of a covered drug from the manufacture of the final
form through the dispenser is impacted by the act. Repackagers have most of the same
requirements that manufacturers do, plus they have many of the wholesale distributor
requirements. Under DSCSA, entities that own the drug may also be “repackagers”,
such as a hospital that repackages bulk medication into individual units used with
automatic dispensers.
3.1

Validation Requirements

A drug is considered a suspect product if there is reason to believe it was potentially
counterfeited, diverted, stolen, part of a fraudulent transaction, intentionally adulterated
or is otherwise unfit to distribute for patient safety reasons. An illegitimate product is
any drug with credible evidence that the product is any of the above.[6] Note that the
designation does not require proof. With this act, the FDA effectively shifts
responsibility onto the seller via the TS not just to verify legitimacy of the product, but
to report and investigate suspected violations. Verification requires establishing
systems and processes to comply with verification requirements, including the ability
to: respond to verification requests from the FDA about suspect products, quarantine
and investigate suspect product, notify trading partners and the FDA of illegitimate
product within 24 hours of determination, respond to notification of illegitimate
product, and maintain records.[1] Drug dispensers must be able to comply with requests
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for information, providing TI, TH, and TS, within two business days while other
stakeholders in the supply chain must respond one business day [1].
3.2

Timeline Requirements

The first milestone of the act allowed the product traceability information to be
provided in either paper or electronic form. Future milestones include dates when the
stakeholders in the supply chain must convert from paper to electronic forms. Other
key dates for the act include when stakeholders must only buy and sell products
encoded with product identifiers (aka serialized products) as well as when verification
must switch from lot-level to package-level identifiers.

Fig. 3. Current Timeline of DSCSA

While some tenants of the act have already been postponed or relaxed, manufacturers
are under pressure to create systems and processes for traceability to be compliant with
the law. However, achieving this goal requires creating a reliable system of record with
appropriate visibility for manufacturers, repackagers, wholesale distributors, and
dispensers.

4

What is Blockchain?

Blockchain is a distributed ledger software technology, meaning it’s a peer-to-peer
(P2P) public ledger maintained over a network of computers.6 Blockchain provides a
method for storing information in a distributed fashion without relying on a centralized
database maintained by a trusted party. The name reveals its method. Transactions are
clustered into blocks of data that are fit together chronologically into a chain using a
hashing algorithm that theoretically makes the confirmed records immutable. The
blockchain is replicated to each participating node on the network and administration
of the blockchain software is orchestrated by consensus of the participating nodes.
The term “blockchain” appears to have originated from a reference to a “chain of
blocks” by Satoshi Nakamoto (pseudonym) in 2008 as a method of validating
6
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ownership of virtual currency in a publicly distributed ledger. Nakamoto’s purpose for
suggesting a peer-to-peer electronic cash system was to make powerful, centralized
third parties obsolete by disintermediating financial transactions.[11] In 2009, the first
application of blockchain technology appeared in the source code for the digital
cryptocurrency Bitcoin. The Bitcoin blockchain is a public ledger of all the Bitcoin
transactions that have ever taken place.
Exposing a transaction’s footprint to the marketplace is called ‘leakage’ and leads to
a host of undesired market behaviors. Preventing leakage is one reason why transaction
data is protected in corporate databases. If the blockchain data is public, then what
prevents competitors from clearly seeing all the transactions? How can a technology
bind the identity for shared data yet provide anonymity at the same time? Blockchain
uses encoding technologies to provide privacy, including hashing algorithms and public
key cryptography.
The heart of a blockchain is a hashing algorithm 7. A hashing algorithm is used to
map data of varying lengths to an output of fixed length. The values returned by a hash
algorithm are called “hash values”, “hash codes”, “digests”, or simply “hashes”. Any
change to the original data would result in a different hash output. Changing a space or
a letter or even changing a lowercase letter to an uppercase letter in the data would
cause the output hash value to be different. Since the input hashes to a unique value,
and it’s infeasible to produce a different block that hashes to the same value, the digest
provides assurance that the original data has not been altered. The Bitcoin Blockchain
relies on SHA-256 to create a 256-byte block that represents the input data. These are
the ‘blocks’ in a blockchain.
In addition to using hashed encoding, blockchain also uses private key cryptography.
Public key cryptography is an encryption system that uses pairs of keys to encrypt and
decrypt data. On the blockchain, each entity is assigned a “public key” available to all
participants and a “private key” that is provided only to the entity it identifies. The keys
are used for authentication. A message or document can be encrypted with a private
key. If the message is legible when it is decrypted using the corresponding public key,
it’s guaranteed that the holder of the private key is the party that encrypted the message.
This digital signature serves as an encrypted, unique identifier associated with a
registered member of the blockchain. Blockchain also supports a concept called M-ofN signatures or “multisig,” meaning that there exists a total of N cryptographic keys,
and at least M of them have to be present to decrypt the data.[12] Since each transaction
includes the digital signature, the parties to the transaction are known. Because it’s an
encrypted key, the real-world identity of the parties can be protected.
As you would expect, the ledger records transactions, like “Billy sends Sally 10
Bitcoins”, but other pieces of data are required in the block as inputs to the hashing
algorithm. Each transaction contains the digital signature of the sender and a timestamp.
The hash value for the previous block is included as input for the current block. This
inclusion forms the ‘chain’, with each new block being linked to the prior block. The
input also includes a nonce, or “number used once”, which is a random numeric value
that creates a hash that will be accepted by the blockchain. Other values are included
as well, but these are the basic components of the input string. Once the inputs are
assembled, the input string is hashed to create a 256-byte value. If the resulting value
7
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is accepted by the network, the block is added to the chain and validated by other
members. The block is added to all the distributed nodes, and the process continues for
the next block.
In a proof-of-work implementation like Bitcoin, miners supply computing resources
and receive compensation for adding valid blocks to the chain as well as transaction
fees for each transaction in the block. Miners race to find a nonce value that will create
an acceptable hash value from the data inputs. The network sets an adjustable threshold
to regulate the difficulty and thus the length of time, for solving the puzzle of
discovering a nonce to complete the block. This mechanism keeps a pace of one new
block added to the chain every 10 minutes. As new blocks are added, they are
considered ‘confirmation’ for the prior blocks. Once six confirmations have been added
on top of a block, the data is considered immutable. At that stage, it’s not feasible with
today’s computers to alter the input data for a block, find a new nonce, add a block with
altered information, and then somehow race ahead to beat all the other computing
resources on the network to rebuild an alternate chain.
While this is a greatly simplified description, it provides a basic framework for
understanding the blockchain technology. Since its introduction, Bitcoin blockchain
has expanded functionality and now allows more types of transactions to be
programmed into the blockchain. After ten years of effective use with Bitcoin,
blockchain technology is now being considered as an alternative to centralized
accounting ledgers and other track-and-trace record keeping systems. Plus, since it’s
the forerunner of all other blockchain solutions, it’s important to understand the
characteristic strengths and weaknesses of the technology.
4.1

Key Characteristics of Bitcoin Blockchain

Let’s take a closer look at the traits that, collectively, position the Bitcoin blockchain
to provide a unique and compelling solution to the marketplace.
Data Structure. Transactions are formatted into blocks that are linked together
using a cryptographic hashing algorithm that takes as input data from prior entries such
that the output is a secure chain of data in which one block cannot be altered without
invalidating the hash.
Distributed. Every node in the network contains a full copy of the dataset.
Decentralized. An algorithm is used by the nodes to validate new entries, with
entries that are validated by a majority of nodes included in the blockchain. Not only
are transactions verified by consensus, but updates to the blockchain software are also
accepted by consensus.
Transparency with Privacy. Users have a digital signature, and each transaction
includes the digital signature of the parties involved, but the signature is not easily
associated with an individual or organization.
Timestamps. Timestamping assures the order of transactions is accurate.
Combining these traits creates a secure, publicly-sharable database that reliably records
the time, content, and parties of each transaction without centralized control for data or
software updates. Compare that to privately-held, centrally managed databases that are
susceptible to alteration of individual data components. To simplify, traditional
technology says “I have my data. You have your data. We have to validate and reconcile
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activity between our databases using a bank or a trusted third party to facilitate. As
soon as the reconciliation concludes, either of us can change our data such that I no
longer trust who you are or your data.” Blockchain technology has the potential to say
“I know who you are. I know who owns this asset. We have a shared record of trusted,
validated transactions; no reconciliation required.”
As a result of these traits, blockchain offers several key benefits compared to
traditional approaches.
Data Integrity. The cryptographic, secure nature of the data structure removes
questions about asset identity, asset ownership, and transaction history. Hashed blocks
make it unfeasible to reverse or tamper with transactions.
Operational Resilience. Distributed data model means data is always accurate and
accessible.
Built-in Audit Trail. Time and parties to transactions are built into the data structure
itself, automatically establishing audit trails while protecting privacy since parties are
identified only by public/private keys.
Ownership. Provides an immutable record of ownership and effectively prevents
double-spending of assets.
The potential to create a secure, shared, immutable record of transactions and asset
ownership is predicted to drive the mass adoption of blockchain technologies as the
next logical step in application evolution. Blockchain instantiates trust as part of the
application.
4.2

Challenges of Bitcoin Blockchain

While the promise of blockchain is great, the associated barriers and risks are also great.
Some of the commonly sited challenges to the adoption of blockchain are listed below.
Blockchain Applications not Impervious. The blockchain is a data store. As with
any other data store, an application is written to leverage the functionality provided by
the data store. Even if the data store is secure, the application may provide
vulnerabilities. Exchanges have been hacked on multiple occasions since they store
both public keys and private keys. Hackers can quickly drain wallets if they are able to
break in and obtain the keys. The underlying assumptions of the benefits of
blockchain have been challenged by two well-publicized events. First, a cyber attack
on Ethereum, a smart contracts blockchain application, improperly diverted $50M
worth of tokens. To counter this attack, 85% of Ethereum users voted for a ‘hard fork’
of the chain, which essentially rolled back the effects of the attack and restarted the
chain before the attack. The remaining 15% of users continued to use the affected data,
referring to it as ‘Ethereum Classic’. The second event involved the bankruptcy of Mt.
Gox, who held 70% of Bitcoin traffic in 2014. During the course of the bankruptcy, it
was discovered that $450 million in Bitcoin was stolen from the bank.[13] These two
events shook confidence in the blockchain software as vulnerabilities became apparent.
Technical Limitations. Scalability is a critical concern as no cryptocurrency
platform approaches processing the number of transactions with the speed of large
payment systems like VISA.[14] Capacity, latency, and query capabilities are quite
limited in comparison to other distributed database systems.[13] Currently, there are no
protocols or standards for interoperability with blockchain. Even with the cryptographic
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nature of blockchain, the breaches and vulnerabilities discussed earlier point toward
remaining security challenges. Plus, with such a widely distributed architecture, there
are simply more entry points for cyber-attacks to occur using methods unforeseen at
this time.
Government Regulation. Healthcare and pharmaceutics are heavily regulated, so
any change in technology would need to be proven to comply with regulations. There
has been no uniform regulation of cryptocurrencies globally let alone addressing the
implications of a blockchains recording transactions for non-monetary assets. Plus,
regulation can create a culture that does not quickly adopt change. “Years of heavy
regulation and a long-standing focus on compliance have co-opted the ability of the
healthcare industry to implement novel data sharing approaches. We now face a critical
need for such innovation. The primary challenge to adoption of blockchain technology
in healthcare is that it is still a nascent technology”.[12] Looking specifically at the US
stock market system, much of the infrastructure has developed ‘organically’ over
decades to meet needs of users and regulators. Switching to a whole new architecture
would be risky, so rapid change of the infrastructure is unlikely.
Conflicting International Law. The General Data Protection Regulation (GDPR)
prevents misuse of personal information collected in databases for citizens of the
European Union. The law was passed April 2016 but goes into effect May 2018. One
tenant of this law is that people have the right to ask for their personal information to
be removed from databases once the need for the data is complete. This requirement is
in conflict with the architecture of blockchain. Because blockchain data is immutable,
by definition the data can’t be removed. However, SQL databases, data changes are
actually logged over time, so the probability that personal data is actually 100% deleted
is not likely. The most likely implementation is that data should not be viewable, usable,
or sharable. This could be accomplished by not putting personal data into the
blockchain. Personal data could be kept in a different data store with a link to the
external data being in the hashed blockchain. Given that decentralized blockchain
applications have no way to remove prior data and no centralized authority to request
removal from, it is essentially the responsibility of the person conducting transactions
and putting data into the chain not to share personal information or not use the service.
Other laws in the EU regulate where data can be stored, with some data not allowed
outside country borders. Because the blockchain is usually replicated to all nodes, any
global blockchain implementation is going to contain data from all participating
countries in all nodes.
While there has been no coordinated global regulation for cryptocurrencies or
blockchain, many countries have begun regulation of their own. Most of the regulation
revolves around what type of asset class cryptocurrencies should be considered,
whether or not exchanges are legal, and enforcement of money laundering and “know
your customer” laws. In addition, there is no consensus on what type of asset class
cryptocurrencies should be considered, even within individual countries. In the United
States, the SEC considers cryptocurrencies as securities, the Commodity Futures
Trading Commission considers them a commodity, while the IRS considers them as

Published by SMU Scholar, 2018

11

SMU Data Science Review, Vol. 1 [2018], No. 2, Art. 4

property. 8 Below is a summary of various governments’ current views on exchanges
and Bitcoin’s use as legal tender.

Table 1.

April 2018 Cryptocurrency and Exchange Status by Country

Government

Exchanges

Japan

Legal, if registered with the Japanese
Financial Services Agency.
Legal, depending on the state. Must be
registered with the SEC.
Legal, depending on the country.

USA
European Union
United
Kingdom
South Korea
China
Singapore
India

Switzerland

Legal
Tender
Yes
No
No

Legal and need to register with the Financial
Conduct Authority.
Legal, if registered with South Korea's
Financial Services Commission.
Illegal

No

Legal, may fall under regulatory purview of
the Monetary Authority of Singapore.
Legal. The Indian government has issued
warnings but does not currently regulate
exchanges.
Legal, need to register with the Swiss
Financial Market Supervisory Authority.

No

No
No

No

Yes

Technocrats. While blockchain may move a process away from central authorities
of banks and government regulation, it may draw its users toward the power of a
technical oligarchy. He who controls processing power may control the blockchain.
Changes to the Bitcoin blockchain software occur via a passive process when holders
representing more than 50% of the network’s mining power adopt or reject a change.
Since consensus decisions are based on mining power, there is a potential for the most
powerful miners to accept only the code changes advantageous to themselves, shoring
up their power. Other situations involving coercion or collusion are also conceivable.
Lessor miners could receive compensation (aka bribes) for accepting code changes of
little importance to themselves. Software changes could be packaged to deceive those
accepting them. Advantageous changes may go unnoticed. This decentralization of
authority over blockchain might leave it vulnerable to sabotage. Theoretically, a
saboteur could compromise the integrity of the blockchain data either by having a much
faster supercomputer than anyone else or by adding enough CPU power to the network
8

Rooney, K. (2018). Your guide to cryptocurrency regulations around the world and where
they are headed.https://www.cnbc.com/2018/03/27/a-complete-guide-to-cyprocurrencyregulations-around-the-world.html
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to control a majority of the mining power and organize a so-called “51% attack”. Thus,
there is concern that this concentrates too much power and decision making in the hands
of technologists, like developers and system administrators. If the system is coded and
managed by a select group of technologists, it could be modified to their advantage or
to the disadvantage of others.
4.3

Addressing limitation of Bitcoin Blockchain

New products and implementation options offer alternatives to the Bitcoin blockchain
implementation to mitigate the challenges listed above. While the term ‘blockchain’
and ‘the blockchain’ are frequently used to refer specifically to the Bitcoin blockchain,
a host of alternative solutions and complementary products have been introduced.
Increasingly, the terms ‘shared ledger’ and ‘distributed ledger technology’ (DLT) as
well ‘blockchain’ are used to generically refer to blockchain solutions. To be a
‘blockchain’, most of the core benefits of the original must be preserved. Obviously, it
must provide a decentralized ledger that provides trusted (immutable) provenance,
transfer, and tracking of asset ownership. A common theme of most, if not all
implementations, is the use of public key infrastructure to secure the asset and hashing
routines to link and protect data integrity.
Alternative implementations feature changes to application scale, the “wallet”
asset, and the access paradigm. Mining is one of the core aspects of the Bitcoin
implementation and was developed to both prevent the fraudulent creation of blocks
and to entice dedication of computing resources to the blockchain. Miners receive
transaction fees and tokens for creating blocks on the chain. Mining is one of the more
controversial aspects of the bitcoin implementation and is modified in or excluded from
alternatives. The processing power required to mine is considered ‘proof of work’.
While proof of work plays a key role in securing the immutable nature of the chain, it
also represents a tremendous amount of wasted computing power. Alternate
implementations have moved to different methods, such as ‘proof of stake’ to provide
a similar functionality while conserving the processing power and thereby increasing
scale and throughput. The Bitcoin blockchain is used to record transactions for a
cryptocurrency, but the “wallet” asset can be any physical or digital asset, such as a
property title, a birth certificate, patient medical records, or ownership of a serialized
drug. Lastly, while the Bitcoin blockchain is a public ledger, a permissioned, private
blockchain implementation may be better for building a pharmaceutical supply chain
ledger. Also, Bitcoin blockchain is purely decentralized. As aspects of software
maintenance are governed by consensus and there no central authority. If you lose your
private key, you lose your bitcoin. There is no authority to which you can appeal but
there is also no central authority to be intimidated by a government. Some of the
alternate implementations, such as what we are proposing for the pharmaceutical supply
chain, require a bit of centralization and control to achieve the goals of the
implementation. Miners are not collecting fees to supply resources, so participants are
likely to supply computing resources and/or pay membership fees to participate.
In addition, there are technologies emerging that are complementary to blockchain
that greatly enhance the impact of the technology. One of the key technologies is ‘smart
contracts’, which is a key feature of Ethereum. Smart contracts are not traditional legal
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contracts. They are blocks of code that ‘autonomously’ execute transactions on the
blockchain if conditions in the code are met. The power and promise of blockchain for
supply chain application tends to lie the combination of three technologies: 1) using
sensors embedded with the product as part of the IoT to record provenance and track
location as well as a host of environmental factors, 2) using smart contracts to execute
transactions when agreed upon conditions are met and 3) using blockchain to create an
immutable record of it all, including current ownership of the asset. In this scenario, it
seems reasonable that technology could remove enough risk to reduce the need for
intermediation. “Blockchain-enabled smart contracts bring more certainty and
reliability to online transactions than has been available to e-commerce environments
for the past twenty years.” [16]. Smart contracts can deliver significant benefits to the
way that we manage supply chains and regulate variable payments.

5

Blockchain and Supply Chain Industry

A range of uses for blockchain have been proposed for the healthcare and
pharmaceutical industries. In 2016 Aptea and Petrovskyb proposed using blockchain to
track the supply chain for excipient pharmaceuticals.[17] As of 2018, a wide assortment
of blockchain programs are underway. We will highlight a selection of the pilot
program implementations mentioned in scholarly works concerning the use of
blockchain in the supply chain, paying special attention to those applications that
provide provenance and traceability of products since those functions are key to
DSCSA compliance. We started by reviewing applications supporting an array of
industries within the supply chain and then moved to those applications supporting the
pharmaceutical supply chain. We then assessed blockchain applications expressing
support for the DSCSA.
Provenance. Provenance conducted a pilot project in Indonesia to enable
traceability in the fishing industry.[18] By using mobile phones, blockchain
technology, and smart tagging, Provenance tracked fish caught by fishermen. The pilot
successfully tracked fish in Indonesia for the first six months of 2016. In July 2016,
Provenance started to work with the UK’s retailer Co-op in order to track fresh food
such as fish, eggs, and dairy through its supply chain. Co-op customers are able to
access information on the product journey through an app on their smartphones.
Through deploying blockchain technology while collaborating with external certifiers
and auditors, Provenance meets the increasing interest of customers to have reliable
information about the source, safety, and sustainability of their products.
Everledger. Working in partnership with Barclays, London-based startup
Everledger offers a blockchain-enabled traceability application providing a fraud
detection system for luxury items such as diamonds, art, and wine. The verification of
the asset is recorded on the blockchain, and insurance companies, owners, and law
enforcement can easily check if an asset has been registered. The main goal is to offer
digital certificates to prevent insurance fraud as it’s estimated that almost 70% of
fraudulent insurance claims are undetected. However, similar to Provenance, the ledger
also offers reassurance about product source, in this case, that diamonds are ethicallysourced from “conflict free” regions amid concerns rebel movements use diamonds to
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finance wars against legitimate governments.[20] Everledger’s diamond registration
application runs on a private Ethereum blockchain, provided by Eris Industries. [18,19]
While Everledger’s diamond industry applications use a certificate system to
authenticate diamonds, for wine Everledger attaches a tamper-evident RFID tag on the
bottle’s cork. Maureen Downey’s company Chai Consulting and Everledger developed
the Chai Wine Vault9 to protect high-end wines. The IBM-based ledger gives each
bottle a unique digital identifier, including over 90 pieces of descriptive data related to
ownership and storage history. The digital data is updated with ownership changes and
storage records and can be used to verify provenance by retailers, warehouses, and
auction houses. [20]
Maersk. The Danish shipping company Maersk has successfully tested the use of
blockchain applications in international logistics. They started by studying logistics
requirements. In 2014, Maersk tracked a shipment of perishable goods from East Africa
to Europe and discovered the shipment required stamps and approvals from up to 30
people, including over 200 different interactions and communications. Afterward,
Maersk partnered with IBM to start working on a version of its blockchain application
based on the Linux Foundation's open source Hyperledger Fabric. IBM and Maersk
conducted a successful proof of concept from September 2016 through February 2017,
tracking three transcontinental shipments of perishable goods. A successful pilot
project was completed in February 2017 that tracked an empty container from a
customer site in France through its global transportation to the container’s destination
in the US.[20] The project is expected to go into production by the end of 2017.10
Walmart. On May 31, 2017, Walmart released the results of the food safety and
traceability protocols test that started in October 2016. The first project involved
tracking produce from Latin America to the United States. The second involved moving
pork products from Chinese farms to Chinese stores. Walmart partnered with IBM to
develop the service. Walmart reported that blockchain helped to reduce the time to track
food from days to minutes.[20]
Bext360. Denver-based startup Bext360’s app and cloud-based software employ
Stellar blockchain to record timestamps and value of transactions on a real-time basis.
It creates records of the origination of coffee beans as well as the price paid for the
beans. Bext360’s first venture will be a kiosk, where farmers can sell beans. A mobile
robot allows coffee buyers to assess the quality and weight of a farmer's product in the
field while a mobile app supports the negotiation of a fair price. The farmers are paid
in real-time via a mobile app.[20]
Intel. In April 2017, Intel revealed a public demonstration that explains how a
seafood supply chain can be tracked using its open-source Sawtooth Lake codebase.11.
Data for four transactions from October 2016 was made public. The data included the
record where a fisherman registered the fish upon catch and then sold it to a fishmonger,
IoT telemetry and temperature data associated with the journey from the ocean to the
fishmonger’s store, the fishmonger's record of selling to a seafood restaurant, and IoT
telemetry and temperature data associated with the journey from the fishmonger to the
seafood restaurant.[20]
9

Winefraud.com. https://www.winefraud.com/chai-wine-vault/.
cointelegraph.com, 2017
11 https://01.org/sawtooth/
10
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Clearly, these efforts demonstrate emerging capabilities achieved through the
application of blockchain technology, especially when coupled with IoT and smart
contract capabilities. Most of these trials are expecting to move beyond initial
experimentation. However, as encouraging as these successful trials are, none are
operating at a scale expected of a global enterprise application.
5.1

Blockchain and Pharmaceutical Supply Chain

We will now consider some proposals, trails, and implementations that are within the
pharmaceutical supply chain. Shireesh Aptea and Nikolai Petrovskyb proposed the use
of blockchain technology to establish provenance and track the excipient supply chain.
Recall that excipients are components of drugs that are not the active ingredient.
Tracking excipients is not part of DSCSA and there is far less risk of theft, diversion,
or counterfeiting of them. But even so, much like people what to know where their fish
comes from, using blockchain to track these components assures the safety and quality
of the entire pharmaceutical supply chain. Of interest in the article was the insight that
blockchain does not alleviate the need for a physical quality audit as data collected from
sensors embedded in a shipment cannot fully guarantee the contents were not stolen,
altered, or replaced with counterfeit goods [18].
Nuco. The blockchain company Nuco attempts to address three common tactics used
in prescription drug fraud: modifying quantities to change the prescription itself,
duplication of prescriptions and visits to many doctors to collect multiple original
prescriptions. When a prescription is produced by a doctor, a machine-readable code is
attached that serves as a unique identifier. This unique identifier is then associated with
the name of the drug, the quantity, the patient, and a timestamp and then recorded on
the blockchain. When the prescription is filled by a pharmacist, the symbol is scanned,
the attempt to fulfill the prescription is compared against the blockchain, and the
pharmacist is quickly informed whether the prescription is eligible to be filled.
HealthChainRx and Scalamed are also working on blockchain solutions to combat
prescription fraud. Several other healthcare-related blockchain applications are in
initial stages, including Medicalchain, Healthcoin, BurstIQ, Factom, GemOS,
HealthCombix, MedRec, Patientory, SimplyVital, and Bowhead. While these
applications were related more to the patient experience or medical records than to
supply chain, it’s telling to have so many projects initiated addressing different aspects
of the healthcare experience [21].
Modum. A recent regulatory change in the EU, known as Good Distribution Practice
of Medicinal Products for Human Use12 requires companies to report any deviations in
temperature or other conditions to the distributor as well as the recipient of the affected
medicinal products. As a result, pharmaceutical drugs are being transported using
expensive refrigerated trucks to maintain conditions that avoided notification, even if
the drug did not need refrigeration to maintain potency [21]. Modum.io AG, a Swiss
start-up, partnered with the University of Zurich to design a system to ensure the safe
transportation of pharmaceutical drugs without the unnecessary use of refrigerated
trucks by focusing on the products that can be stored at ambient temperatures (15°–
25 °C). Modum built a prototype and completed a first pilot project together with
12
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pharmaceutical distributors. From July 7th to August 12th 2016, a pilot project was
conducted and medical goods were shipped weekly from one supplier to a
pharmaceutical wholesaler. A Modem sensor monitors the temperatures of the
medicines during transport and the data is transferred to the Ethereum blockchain after
the trip. A Solidity-based smart contract compares the data against regulatory
requirements, and if all the required conditions are fulfilled, the product is released.
These results are publicly accessible and reported back to the receiver as well as to the
distributor. Currently, modum.io AG is planning for a second pilot project with over
500 shipments with more distributors and wholesalers. Must like DSCSA, the Falsified
Medicines Directive (FMD)13 requires individual pharmaceutical packages to have a
serial number to support tracking of medications at ‘per use’ level by 2019. Once
packages are serialized, results may also be available to end customers [21].
Gemalto. Gemalto has teamed up with an insurance company that covers the
delivery of temperature-sensitive medicines from drug manufacturer to hospitals
located in hot climates. Digital thermometers are used to record the temperature of
drugs regularly and the data is added to a blockchain ledger. Blockchain helps to govern
that process and provide assurance that safety requirements are met [21].
Blockverify. Blockverify is a US company trying to introduce Blockchain into the
global pharmaceutical supply chain to avoid counterfeit and forgeries. [20] Their main
business areas include pharmaceuticals, luxury items, diamonds, and electronics.
Blockverify conducted a pilot project in the pharmaceutical sector using the Bitcoin
blockchain together with a private side chain. Every product has its private key stored
in the public blockchain that can be verified by anyone. With a track and trace number,
it is possible to trace change of ownership, thus every change will be recorded in the
private blockchain [21].
5.2

Blockchain application targeting DSCSA compliance

Chronicled, a San Francisco-based blockchain startup, in conjunction with LinkLab, a
life sciences supply chain consultancy, launched Mediledger, a blockchain-based
compliance protocol to satisfy DSCSA.[20]
Like others, Chronicled is not limited
to pharmaceuticals and is expanding their service to luxury items. Their blockchain is
an open registry where information about buyers and sellers are stored. Luxury items
are tagged for identification which allows everyone to check the history of buyers and
sellers [21].
Mediledger provides provenance and traceability of drug shipments, supply chain
integrity, and real-time global supply feedback using IoT. MediLedger’s stated purpose
is to demonstrate compliance with the DSCSA and to create an operable system in
which multiple parties can verify and transfer pharmaceutical products with absolute
trust in their authenticity, based on blockchain technology. In March 2018, MediLedger
released a year-end report in which they stated, “First, the Project's blockchain-based
system appears to fully meet the requirements set forth by DSCSA and is capable of
acting as the interoperable system for the pharmaceutical supply chain prescribed in the
Act. In addition, MediLedger has proven that it can meet the data privacy requirements
13
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of the pharmaceutical industry itself. In particular, it can guarantee that all supply chain
handshake transactions posted to the blockchain are fully obfuscated, ensuring that no
business intelligence is leaked. This will allow nodes in the blockchain system to be
hosted by numerous unique parties while both safeguarding sensitive transactions and
ensuring the immutability of each supply chain handshake transaction.”
5.3 Encouraging Participation
So far, the literature has assumed that pharmaceutical companies will comply with the
law, regardless of the cost, because of the governance power of the FDA. However, can
the FDA afford to punish all drug manufacturers and other supply chain participants if
there is a widespread inability or unwillingness to comply? Perhaps more “carrot” and
less “stick” will help encourage participation. Below are some ideas to incent
pharmaceutical companies to collaborate in the building of a shared ledger.
Expedite the approval process. This would reduce time to market for new drugs
and give manufacturers quicker access to revenue that would help cover R & D costs.
To protect consumers the FDA shouldn’t cut corners, they should devote more
resources to the approval process of a drug that a manufacturer will agree to put on a
distributed ledger.
Grant patent extensions. This will allow the manufacturers to sell drugs they
develop at a premium for longer before generics can legally be sold that eat into their
market share. It can be argued that this would hurt consumers since they would have to
pay a premium for longer, but manufacturers could reduce price and maintain the same
profitability since their volume sold would increase.
Mask the public keys associated with each distributed ledger participant.
Keep all metadata encrypted inside of the blocks so that competitors can’t analyze the
supply chain to gain competitive information. Auditors and regulatory bodies can be
granted access to decrypt the information inside of a block in case of an audit or
inspection [22].

6
6.1

Ethical Considerations
Traceability of Pharmaceuticals

Advertisers use labels like “organic”, “wild caught”, “sustainable sources”, “100%
Colombian” to entice consumers to their premium brands. The reality is most of those
claims can’t be substantiated. In fact, without DNA testing it’s difficult to tell if the
white tuna ordered in a sushi restaurant truly is tuna or a cheaper substitute. Some of
the blockchain projects above will prove if consumers are willing to buy brands with
proven provenance and a traceable supply chain. Traceability of food sources will
provide consumers with more choices. Traceability of luxury items may save insurance
companies from fraud. Traceability of diamonds could reduce funds flowing to rebels
in conflict zones who use them to finance their violence. In cases where there are human
rights violations involved in the production of goods, the technology has the potential

https://scholar.smu.edu/datasciencereview/vol1/iss2/4

18

Scott et al.: Evaluating Feasibility of Blockchain Application for DSCSA Compliance

to stop unethical and illegal practices, including slavery [20]. Traceability of
pharmaceuticals is a matter of life or death. Counterfeit drugs cost lives around the
world. In the US, we had the Heparin incident described above, but globally thousands
of lives are lost when Malaria drugs are replaced with counterfeit drugs. As traceability
is rapidly becoming a capability, ethically, we are bound to use these techniques to
prevent criminals from tainting the prescription drug supply. While complying with the
DSCSA will be difficult and expensive, it’s also an ethically compelling concept,
especially if it can be implemented globally.
6.2

Data Privacy

Perhaps the greatest ethical challenge facing data science today is the dual-edge sword
of data privacy. When to keep data hidden and when to reveal or use data is not only a
sensitive topic, it’s one for which there are complex and changing global laws and
growing consumer sensitivity. While patients may be willing to risk releasing their data
into collections of population health data for the promise of longer and healthier lives,
they may not want to release the same information for market research and the promise
of more targeted advertising campaigns. It’s an area where opinions on ethical behavior
differ widely, leaving lots of ‘gray’ territory. Having the local pharmacy publish your
prescription drug purchases in the Sunday Times is not ethical. Pharmacies legally sell
data concerning prescription drug purchases, anonymized to a zip code, for market
research. People with a rare disorder may feel the zip code is not anonymized
adequately while others purchasing a widely-prescribed drug may not care. Having the
analytic power to identify when $40 million of opioids are shipped into a small market
and holding those drug manufacturers accountable for the resulting explosion of opioid
abuse would probably be considered an ethical application by most data science
professionals14. Thus, our concept of ‘ethical’ treatment of data is based on how the
data is used and data scientists must be informed not only about the laws but also about
how the findings of any specific research effort might be used, even if the stated purpose
seems noble.
DSCSA. DSCSA is not causing additional data to be collected or distributed for
individuals. In fact, the dispensing of the drug pursuant to a prescription is explicitly
excluded from the law. Thus, DSCSA does not represent incremental data privacy
issues for individuals. What is at risk are the trade secrets and privacy of each
participating business entity. Industrial espionage is real and exposing transactional
patterns to the marketplace could be a threat to the participants’ business. Thus,
whatever data store is used must protect the participating entities from gaining unfair
knowledge of inventory or trade practices of others in the supply chain. Since the point
of DSCSA is to create transparency, this business need may be counter to enforcement
of the Act. In this regard, blockchain offers some advantages because of the encryption.
A blockchain does not easily lend itself to that type of analysis. The main requirement
is to tightly control who would have access to the cryptographic keys as that capability
14

Wamsley, L. Drug Distributors Shipped 20.8 Million Painkillers To West Virginia Town Of
3,000. Available: https://www.npr.org/sections/thetwo-way/2018/01/30/581930051/drugdistributors-shipped-20-8-million-painkillers-to-west-virginia-town-of-3-00.

Published by SMU Scholar, 2018

19

SMU Data Science Review, Vol. 1 [2018], No. 2, Art. 4

would unlock more ability to analyze the transaction data for patterns outside the stated
purpose.
Blockchain. Likewise, the use of blockchain to meet the requirements of DSCSA
does not present new data privacy dilemmas specifically relative to prescription drugs
as the ethical dilemmas are common to all types of data that can be traced to individuals
or communities. With that said, blockchain does present two unique data privacy
dilemmas by nature of the technology.
First, blockchain data is ‘immutable’, it never goes away. Unlike an RDMS or any
other data store, the data can’t simply be over-written with corrected information or
‘blanked out’. The data has to be updated with information in a new block and all
subsequent reporting would need to read the entire blockchain or risk using incorrect
data. The GDPR, which requires that EU citizens be able to request their personal
information be removed from any data store, has implications for blockchain since it’s
not possible to delete data. This is one reason why a lot of implementations don’t use
blockchain alone. The blockchain is used to record the transactional information that
should not change, but personally identifiable information that could change is
normally stored in a more traditional data store with the link to that data encoded in the
blockchain. In fact, since data in a blockchain is hashed, it can only be accessed and
read by people who have the appropriate software to do so, which is why it’s viewed
as a more secure data store. As many investors in Bitcoin have discovered, if you lose
your private cryptographic key, your bitcoin is unrecoverable. Going deeper, what if
the original ownership entry being reported by the blockchain is incorrect? What if the
person populating the blockchain with property deeds simply replaces their name as the
rightful owner? What if medical records recorded in blockchain record an incorrect
diagnosis or treatment that was not provided to that patient? HealthCombix, in
collaboration with PointNurse, is attempting to address this by introducing a service
provided by nurses to ensure that the data entered into the immutable blockchain record
is accurate and that the patient understands how to access, update, and grant access to
their records [23]. More so than other data stores, the potential impact of incorrect data
being instantiated into the blockchain must be considered by the designers with
contingencies to address that occurrence built into the application if the data coming
into the application could be wrong.
Second, because the data is encoded and parties to a transaction are obscured by the
use of cryptographic keys, blockchain can be used to protect the identities of parties
involved in criminal activities. Since a public blockchain has no centralized authority,
there is no organization to serve a warrant to force disclosure of activity or identities.
This has been an ongoing criticism of bitcoin and why it is so closely associated with
the Dark Web. Decentralization is also why citizens in countries with corrupt banking
systems are willing to trust Bitcoin instead of their state-governed bank. As with most
technology, the ethical dilemma lies with the use case, not the technology.

7

Conclusion

When considering the viability of blockchain-based applications, most sources agree
that the technology’s biggest barrier is simply that it’s too new. Regulations have not
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been created. Technical understanding of the technology is limited and has not yet
spread. Successful pilots have not been turned into successful applications at scale.
However, last year, this same research group conducted a survey of literature for
blockchain. At that time, there were a plethora of scholarly articles explaining
blockchain and proposing applications for the new technology beyond cryptocurrency,
mostly in the financial sector. This year, the articles have shifted to presentations and
evaluations of pilot programs, with many articles presenting case studies on several
different use cases relevant to supply chain. We discovered a wide array of pilot
programs, including programs backed by significant industry leaders and global
enterprise organizations like IBM, Wal-Mart, and Maersk, in addition to the expected
array of start-up efforts. Most articles still predicted growth for the adoption of
blockchain, even if they disputed the hype that blockchain would be an industry
disruptor. We have demonstrated that blockchain, in theory, offers unique benefits to
meet requirements for supply chain traceability. Yet, the technology is still unproven
at the scale and performance that will be required to integrate into supply chain
applications. While MediLedger’s year-end statement is promising, their industry
claims must be substantiated.
Certainly, the social climate supports traceability, if not the technology to achieve it.
Consumers want more information about the provenance and traceability of foods so
they will be more informed about quality and sustainability. How much more so would
patients want assurances that their medications are safe and effective? With so much
value in the pharmaceutical supply chain and the risk of death a real possibility, the cost
justification is not difficult if traceability can prevent counterfeit or compromised drugs
from reaching patients.
On the other hand, while blockchain offers promise, the current state of the supply
chain industry may make adopting blockchain difficult. Blockchain is a data store.
When coupled with IoT technology and smart contracts, it creates a compelling vision
for a new paradigm, but what blockchain lacks is the thing supply chain needs the most
to support automation: standardized data models. The supply chain industry is simply
not prepared to adopt a shared ledger technology until/unless there is more
commonality in how participants exchange data [24]. With that in mind, Modum may
have the right approach. Instead of starting off with a full-fledged solution for drug
traceability, solve smaller problems, gain experience, and build to a wider solution.
Maersk seems to be taking the same “start small, gain experience” approach to their
implementation. Focusing on the requirements for DSCSA, in essence, carves out a
subset of the overall pharmaceutical supply chain functionality and allows focus on a
portion of the problem with a stated data model.
2018 will be a pivotal year for blockchain adoption. As pilot programs end,
organizations will decide if they are going to continue investing in the technology.
Apparently, several key players recently confirmed that position. Forbes reported on a
recent panel discussion about blockchain adoption from the technology community.
Speakers included Anant Kadiyala, Director of Blockchain & Industry Solutions at
Oracle; IBM's David Noller, Executive Architect Watson IoT - Blockchain and
Industry 4.0; and Steven Kim, a Senior Director at SAP. The user community was
represented by Jeff Denton, the Senior Director of Global Secure Supply Chain at
AmerisourceBergen, one of the largest pharmaceutical distributors in the world. For a
wide variety of use cases, Mr. Denton believes you start by assuming blockchain will

Published by SMU Scholar, 2018

21

SMU Data Science Review, Vol. 1 [2018], No. 2, Art. 4

be the answer and only explore other technologies if you can prove blockchain doesn't
work. According to Mr. Kim of SAP, "2018 will be a milestone year that we will see
the adoption of a first set of blockchain solutions in enterprise applications - from
securing the pharmaceutical supply chain to eliminating inefficiency in international
logistics." Both Mr. Noller of IBM and Mr. Kadiyala of Oracle agree that 2018 will be
the year that blockchain moves from pilots to everyday usage in business applications.15
Since DSCSA compliance is not required until 2023, that provides time for the market
to gain experience and knowledge while blockchain technology matures.

8

Summary

By 2023, DSCSA requires the consistent traceability of pharmaceutical products from
manufacturer to dispenser within the United States. Participants in the supply chain are
expected to verify the chain of ownership, detect suspicious activity, and respond
accordingly as outlined by the law. In addition, participants must be able to quickly
respond to requests for information from enforcement officials. The final outcome of
Title II will be the creation of an electronic, interoperable traceability system for
pharmaceutical products at the package-level. The goal is to use real-time data capture
to detect, respond to, and report potentially illegitimate drugs faster and more
effectively before they can become a safety hazard to patients. The DSCSA was created
to curb the circulation and sale of illegitimate pharmaceutical products. However,
achieving this goal requires creating a reliable system of record with appropriate
visibility to identify legitimate pharmaceuticals for all participants in the supply chain.
Since members in the supply chain have compelling business reasons not to share
information on inventory, a key challenge to ensuring compliance with traceability
requirements will be establishing trust among stakeholders.
Blockchain applications are uniquely designed to provide traceability and to
introduce trust into a trust-less system. As such, providing traceability of
pharmaceuticals through the supply chain is a suitable use case for a blockchain
implementation. This review demonstrated how a blockchain technology can provide
functionality that benefits supply chain management in general and traceability of
pharmaceuticals in particular. We identified several blockchain pilot programs relevant
to traceability conducted by both global enterprises and start-up companies. However,
none of these have the maturity to prove blockchain can operate at the scale required to
support DSCSA compliance. Supply chain applications focused on compliance with
track-and-track regulations like DSCSA may be the turning point for blockchain to
prove it’s worthy of the hype as an industry disruptor.
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Appendix
This project originated as a proof of concept. Our efforts failed, but in the interest of
disclosure, we wanted to list some resources and methods we tried in hopes that it will
help others. Initial efforts focused on using the Interplanetary Database (IPDB) which
was touted as an internet-scale blockchain database. However, according to a post on
ipdb.io in January 2018, “The world has changed, and funding to maintain and operate
IPDB while maintaining its core values became an insurmountable struggle.” 16 We
speculate that funding may have dried up for IPDB due to the upcoming GDPR law.
Since ipdb.io cited that BigChainDB17 had been instrumental in their test network
development, a combination of BigChainDB and MongoDB running in a Linux
environment was next explored. While some limited success was obtained by following
online documentation, we did not find the BigChainDB implementation had the ease of
use required for the timeframe we were seeking to build the POC. Although
BigChainDB seems to be a promising commercial product to build blockchains, the
support is too expensive for an academic exercise and the open source implementation
proved to be difficult.
After some searching for a simpler method, a Python tutorial was found on a
blogpost at hackernoon.com that showed a straight forward method for building a
blockchain. The code tutorial from the hackernoon article details how to build Rest
APIs with Python libraries hashlib, json, and flask. The application operates using
HTTP requests. The author of the tutorial suggests the use of cURL or Postman for
testing the HTTP requests. Postman is cost prohibitive for testing due to the limited
number of free transactions (1,000) while cURL did not interact well with Windows
10. We discovered an open source application named Advanced Rest Client which we
used to test transferring data between the blockchain application and the client. While
the code to read and write data was relatively straightforward, communication between
nodes was unattainable.
Just after conclusion of our research, Amazon announced availability of their free
blockchain templates. The authors recommend exploring those capabilities.

16
17

IPDB webpage. Retrieved from https://ipdb.io/
https://docs.bigchaindb.com/en/latest/
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